ArticleBiological psychiatry global open science2022
Identifying the Common Genetic Basis of Antidepressant Response.
Open access · goldAbstract read
In one paragraph
Article in Biological psychiatry global open science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 4 pooled it
12.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Genome-wide meta-analyses of non-response to antidepressants provide insights into underlying molecular genetics and suggest potential pharmacotherapies.Molecular psychiatry · 2026Pooled it
- Genome-wide association meta-analysis and rare copy number variant analysis of treatment-resistant depression.Molecular psychiatry · 2025Pooled it
- Pharmacogenomic scores in psychiatry: systematic review of current evidence.Translational psychiatry · 2024Pooled it
- Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis.Translational psychiatry · 2024Pooled it
- Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study.Neuropsychobiology · 2023Trial
- Polygenic heterogeneity in antidepressant treatment and placebo response.Translational psychiatry · 2022Trial
- Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial.Translational psychiatry · 2022Trial
- Understanding antidepressant change patterns in the UK Biobank.The British journal of psychiatry : the journal of mental science · 2026Article
- Can Psychiatric Genetics Advance Without Incorporating a Life Course Perspective?Biological psychiatry · 2026Review
- Pharmacotherapy of major depressive disorder in older adults: from an evidence-informed stepwise algorithm to precision medicine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Genetics to Improve Outcomes in Schizophrenia (GENios): A within-case molecular genetic study protocol.PloS one · 2026Article
- Integrating multi-polygenic scores for enhanced prediction of antidepressant treatment outcomes in an East Asian population.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Genetic influences on antidepressant side effects: a CYP2C19 gene variation and polygenic risk study in the Estonian Biobank.European journal of human genetics : EJHG · 2025Article
- Tissue-Specific Chromatin Accessibility Regions and Transcription Factor Binding Sites in Pig Brain and Endocrine Tissues.Molecular neurobiology · 2025Article
- Prediction of treatment-resistant depression using the 23andMe survey data.Scientific reports · 2025Article
- Analysis of Genomic and Transcriptomic Data Revealed Key Genes and Processes in the Development of Major Depressive Disorder.International journal of molecular sciences · 2025Article
- Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets?European archives of psychiatry and clinical neuroscience · 2025Review
- Pathway-Specific Polygenic Scores for Predicting Clinical Lithium Treatment Response in Patients With Bipolar Disorder.Biological psychiatry global open science · 2025Article
- Exploring depression treatment response by using polygenic risk scoring across diverse populations.American journal of human genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors at 20 institutions in 14 countries.
Oliver PainSocial, Genetic and Developmental Psychiatry Centre, King's College London, London, United Kingdom.
Karen HodgsonSocial, Genetic and Developmental Psychiatry Centre, King's College London, London, United Kingdom.
Vassily TrubetskoyDepartment of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Medical Psychology, Berlin, Germany.
Stephan RipkeDepartment of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Medical Psychology, Berlin, Germany.
Victoria S MarshePharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Mark J AdamsDivision of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom.
Enda M ByrneInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
Adrian I CamposDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Tania Carrillo-RoaDepartment of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
Annamaria CattaneoBiological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy.
Thomas D AlsLundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus University, Aarhus, Denmark.
Daniel SoueryLaboratoire de Psychologie Medicale, Université Libre de Bruxelles, Brussels, Belgium.
Mojca Z DernovsekUniversity Psychiatric Clinic, University of Ljubliana, Ljubljana, Slovakia.
Chiara FabbriSocial, Genetic and Developmental Psychiatry Centre, King's College London, London, United Kingdom.
Caroline HaywardMRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom.
Neven HenigsbergDepartment of Psychiatry, Croatian Institute for Brain Research, University of Zagreb Medical School, Zagreb, Croatia.
Joanna HauserPsychiatric Genetic Unit, Poznan University of Medical Sciences, Poznan, Poland.
James L KennedyTanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Eric J LenzeHealthy Mind Lab, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
Glyn LewisDivision of Psychiatry, University College London, London, United Kingdom.
Daniel J MüllerPharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Nicholas G MartinDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Benoit H MulsantDivision of Adult Neurodevelopment and Geriatric Psychiatry, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Ole MorsPsychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.
Nader PerroudDepartment of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.
David J PorteousInstitute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Miguel E RenteríaDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Charles F ReynoldsDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
Marcella RietschelDepartment of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Heidelberg University Faculty of Medicine in Mannheim, Mannheim, Germany.
Rudolf UherDepartment of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
Eleanor M WigmoreDivision of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom.
Wolfgang MaierDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
Naomi R WrayInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
Katherine J AitchisonDepartment of Psychiatry, Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada.
Volker AroltDepartment of Psychiatry, University of Münster, Münster, Germany.
Bernhard T BauneDepartment of Psychiatry, University of Münster, Münster, Germany.
Joanna M BiernackaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.
Guido BondolfiDepartment of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.
Katharina DomschkeDepartment of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Freiburg, Germany.
Masaki KatoDepartment of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Qingqin S LiNeuroscience Therapeutic Area, Janssen Research and Development, LLC, Titusville, New Jersey.
Yu-Li LiuCenter for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Taipei, Taiwan.
Alessandro SerrettiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Shih-Jen TsaiDepartment of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
Gustavo TureckiDepartment of Psychiatry, Douglas Institute, McGill University, Montreal, Quebec, Canada.
Richard WeinshilboumDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
GSRD Consortium
Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium
Andrew M McIntoshDivision of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom.
Cathryn M LewisSocial, Genetic and Developmental Psychiatry Centre, King's College London, London, United Kingdom.
Genomics (United Kingdom) · GBInstitute of Genetics and Cancer · GBKing's College London · GBCentre for Addiction and Mental Health · CAQIMR Berghofer Medical Research Institute · AUUniversité Libre de Bruxelles · BEUniversity College London · GBThe University of Queensland · AUUniversity of Edinburgh · GBBroad Institute · USHumboldt-Universität zu Berlin · DEAarhus University · DKAarhus University Hospital · DKDalhousie University · CAHeidelberg University · DEJanssen (United States) · USMayo Clinic · USPoznan University of Medical Sciences · PLThe University of Melbourne · AUUniversity Hospital of Geneva · CH
Funding
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M7/7 Psychiatric Genomics Consortium: Finding actionable variationU01MH109532 · NIMH · WASHINGTON UNIVERSITY · PI AGRAWAL, ARPANA, EDENBERG, HOWARD J · 2016 to 2020
$3.1M1/7 Psychiatric Genomics Consortium: Finding actionable variationU01MH109528 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SULLIVAN, PATRICK F · 2016 to 2020
$2.5MMedical Research Council G0701420Medical Research Council MC_PC_17209Medical Research Council MC_UU_00007/10NIGMS NIH HHS U19 GM061388NIMH NIH HHS U01 MH109528NIMH NIH HHS U01 MH109532Wellcome Trust
Abstract
Background: Antidepressants are a first-line treatment for depression. However, only a third of individuals experience remission after the first treatment. Common genetic variation, in part, likely regulates antidepressant response, yet the success of previous genome-wide association studies has been limited by sample size. This study performs the largest genetic analysis of prospectively assessed antidepressant response in major depressive disorder to gain insight into the underlying biology and enable out-of-sample prediction. Methods: Genome-wide analysis of remission ( Results: Neither genome-wide association study identified genome-wide significant associations. Single nucleotide polymorphism-based heritability was significantly different from zero for remission ( Conclusions: This study demonstrates that antidepressant response is influenced by common genetic variation, has a genetic overlap schizophrenia and educational attainment, and provides a useful resource for future research. Larger sample sizes are required to attain the potential of genetics for understanding and predicting antidepressant response.
Indexed as
Antidepressant responseDepressionGeneticsGWASMDDPolygenic score
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.